2'-O-alkylated oligoribonucleotides and phosphorothioate analogs

Details 2'-O-alkylated oligoribonucleotides and phosphorothioate analogs 2'-O-alkylated oligoribonucleotides and phosphorothioate analogs

1991-11-19

2000-03-07

Crane, L Eric

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

514 44, C07H 2100

Patent

active

060342331

ABSTRACT:
Methods of modulating the activity of the TAR element of HIV are provided. Oligonucleotides having 6 to 50 bases and at least one 2'-O alkyl modification and selected sequences are disclosed.

REFERENCES:
patent: 4806463 (1989-02-01), Goodchild et al.
patent: 5166195 (1992-11-01), Ecker
patent: 5264423 (1993-11-01), Cohen et al.
patent: 5276019 (1994-01-01), Cohen et al.
patent: 5455158 (1995-10-01), Vogel et al.
patent: 5474935 (1995-12-01), Chatterjee et al.
Jacks et al, "Characterization of Ribosomal Frameshifting in HIV-1 `gag-pol` Expression", Nature, vol. 331, No. 21, pp. 280-283, 1988.
Dayton et al., "Functional Analysis of CAR, the Target Sequence for the Rev Protein of HIV-1", Science, vol. 246, pp. 1625-1629, Dec. 1989.
Agrawal et al., Proc. Natl. Acad. Sci. USA 85:7079 (1988).
Agrawal et al., Proc. Natl. Acad. Sci. USA 86:7790 (1989).
Arnott and Selsing, J. Mol. Biol. 88:509 (1974).
Berkhout et al., Cell, 59:273 (1989).
Broitman et al., Proc. Natl. Acad. Sci USA 84:5120 (1987).
Casey et al., Science 240:924 (1988).
Dayton et al., Science 246:1625 (1989).
Feng and Holland, Nature 334:165 (1988).
Garcia et al., EMBO J., 87:765 (1989).
Goodchild et al., Proc. Natl. Acad. Sci. USA 85:5507 (1988).
Hanvey et al., Proc. Natl. Acad. Sci. USA 85:6292 (1988).
Haseltine and Wong-Staal, Scientific American, 52 (Oct., 1988).
Henthorn et al., Proc. Natl. Acad. Sci. USA 85:6342 (1988).
Jaeger et al., Proc. Natl. Acad. Sci. USA 86:7706 (1989);.
Larson and Sells, Mol. Cell. Biochem. 74:5 (1987).
Laspia, et al., Cell, 59:283 (1989).
Le et al., Nucl. Acids Res. 16:5153 (1988).
Letsinger, Proc. Natl. Acad. Sci. USA 86:6553 (1989).
Loose-Mitchell, TIPS, 9:45-47 (1988).
Malter, Science 246:664 (1989).
Marcus-Sekura, Anal. Biochemsitry, 172:289-295 (1988).
Matsukura et al, Proc. Natl. Acad. Sci. USA 84:7706 (1987).
Mori et al., Nucleic Acids Res. 17:8027 (1989).
Resnekov et al., J. Biol. Chem. 264:9953 (1989).
Ratner et al., Nature 313:277 (1985).
Sharp and Marciniak, Cell, 59:229 (1989).
Stevenson and Iversen, J. Gen. Virol. 70:2673 (1989).
Shibahara et al., Nucl. Acids Res. 17:239 (1989).
Stein & Cohen, Cancer Research, 48:2659-2668 (1988).
Sarin et al., Proc. Natl. Acad. Sci. USA 85:7448 (1988).
Tinoco, Jr. et al., Cold Spring Harb. Symp. Quant. Biol. 52:135 (1987).
Tuerk et al., Proc. Natl. Acad. Sci. USA 85:1364 (1988).
Turner and Sugimoto, Annu. Rev. Biophys. Biophys. Chem. 17:167 (1988).
Van der Krol et al., BioTechniques, 6:958-973 (1988).
Walder, Genes & Development, 2:502-504 (1988).
Zaia et al., J. Virol. 62:3914 (1988).
Zamecnik et al., Proc. Natl. Acad. Sci. USA 83:4143 (1986).
Zon, Journal of Protein Chemsitry, 6:131-145 (1987).
Zon, Pharmaceutical Research, 5:539-549 (1988).
Guo et al., "Sequence Analysis of Original HIV-1," Nature, 348, 745-746 (1991).
Chang et al., "Inhibition of Rous Sarcoma Virus Replication by Antisense RNA," J. Virology, 61(3), 921-924 (1987).
Scheit, Nucleotide Analogs, Synthesis and Biological Function, Wiley-Interscience, 1980, New York, pp. 171-172.
McCune et al., "The SCID-hu Mouse: Murine Model for the Analysis of Human Hematolymphoid Differentiation and Function," Science, 241, 1632-1639 (1988).
Namikawa et al., "Infection of the SCID-hu Mouse by HIV-1," Science, 242, 1684-1686 (1988).
"Antisense Antiviral Drug in Clinical Trials," Antiviral Agent Bulletin, 5(6), 161-163 (1992).
"Antisense HPV Drug Enters Phase II Trials," Antiviral Agent Bulletin, 5(12), xx-xx (1992).
BioWorld Today, Dec. 20, 1993, see p. 3, column 2, paragraphs following first bullet.
"ISIS 2105 Clarification," Antiviral Agent Bulletin, 6(2), 42-43 (1993).
Offensperger et al., "In vivo Inhibition of Duck Hepatitis B Virus Replication and Gene Expression by Phosphorothioate Modified Antisense Oligonucleotides," EMBO J., 12(3), 1257-1262 (1993).
Simons et al., "Antisense c-myb Oligonucleotides Inhibit Intimal Arterial Smooth Muscle Cell Accumulation in vivo" Nature, 359, 67-70 (1992).
Burch et al., "Oligonucleotides Antisense to the Interleukin 1 Receptor mRNA Block the Effects of Interleukin 1 in Cultured Murine and Human Fibroblasts and in Mcie," J. Clinical Invest., 88, 1190-1196 (1991).
Kitajima et al., "Ablation of Transplanted HTLV-1 Tax-Transformed Tumors in Mice by ANtisense Inhibition of NF-.kappa.B," Science, 258, 1792-1795 (Dec. 11, 1992).
Higgins et al., "Antisense Inhibition of the p65 Subunit of NF.kappa.B Blocks Tumorigenicity and Causes Tumor Regression," Proc. Nat. Acad. Sci. USA 90, 9901-9905 (1993).
Vlassov, "Inhibition of Tick-Borne Viral Encephalitis Expression Using Covalently Linked Oligonucleotide Analogs," reported at the conference entitle Oligonucleotides As Antisense Inhibitors of Gene Expression: Therapeutic Implications, Nat. Cancer Inst & Nat. Inst. Allergy & Infectious Diseases co-sponsors, Rockville, MD, Jun. 18-21, 1989, see Abstract supplied.
Cohen et al., "The New Genetic Medicines--Synthetic Strands of DNA Are Being Developed as Drugs. Called Antisense and Triplex Agents, They Can Potentially Attack Viruses and Cancers Without Harming Healthy Tissue," Scientific American, pp. 76-82, Dec. 1994.
Mirabelli et al., "In Vitro and In Vivo Pharmacologic Activities of Antisense Oligonucleotides," Anti-Cancer Drug Design, 6, 647-661 (1991).
Goodman and Gilman's The Pharmacological Basis of Therapeutics, Sixth Ed., 1980, MacMillan Publ. Co., Inc., New York, pp. 1-2.
R. G. Douglas, Jr., "Antimicrobial Agnets," Ch. 51 in Goodman and Gilman's The Pharmacological Basis of Therapeutics, Eighth Ed., 1990, Pergamon Press, Inc., New York, pp. 1182-1201.
Yarchoan et al., "Correlations between the In vitro and In vivo Activity of Anti-HIV Agents: Implications for Future Drug Development," J. Enzyme Inhibtion, 6, 99-111 (1992).
Spectro et al., "Human Immunodeficiency Virus Inhibition Is Prolonged by 3'-Azido-3'-Deoxythymidine Alternating with 2', 3'-Dideoxycytidien Compared with 3-40-Azido-3'-Deoxythymidine Alone," Antimicrobial Agents and Chemotherapy, 33(6), 920-923 (1989).
Doulerice et al., "Inhibition by AZT of HIV-1 Replication in Acutely Infected U-937 Cells," J. Leukocyte Biol., 47, 498-505 (1990).
Fridland et al., "Relationships of Deoxynucleotide Changes to Inhibition of DNA Synthesis Induced by the Antiretroviral Agent 3'-Azido-3'-deoxythymidine and Release of its Monphosphate by Human Lymphoid Cells (CCRF-CEM)," Molecular Pharmacology, 37, 665-670 (1990).
Mansuri et al, "Comparison of In Vitro Biological Properties and Mouse Toxicities of Three Thymidine Analogs Active Against Human Immunodeficiency Virus," Antimicrobial Agents and Chemotherapy, 34(4), 637-641 (1990).
Volsky et al., "Evaluation of Multiple Parameters of HIV-1 Replication Cycle in Testing of AIDS Drugs In Vitro," Antiviral Research, 17, 335-347 (1992).
Lambert et al., "Synergistic Drug Interactions of an HIV-1 Protease Inhibitor with AZT in Different In Vitro Models of HIV-1 Infection," Antiviral Research, 21, 327-342 (1993).
Panneer et al., "Inhibition of HIV-1 Replication in H9 Cells by Nystatin-A Compared with Other Antiviral Agents," AIDS Res. Human Retroviruses, 9(5), 475-481 (1993).
Spinolo et al., "Toxicity of Human p53 Antisense Oligonucleotide Infusions in Rhesus macacca," Proc. Ann. Meeting Am. Assoc. Cancer Res., 33, Abstract No. 3125 (1992).
Sarmiento et al., "In vivo Toxicological Effects of rel A Antisense Phosphorothioates in CD-1 Mice," Antisense Research and Development, 4, 99-107 (1994).
Iversen et al., "Pharmacokinetics of an Antisense Phosphorothioate Oligodeoxynucleotide Against rev from Human Immunodeficiency Virus Type 1 in Adult Male Rat Following Single Injections and Continuous Infusion," Antisense Research and Development, 4, 43-52 (1994).
In vivo Studies with Phosphorothioate Oligonucleotides: Pharmacokinetics Prologue, Anticancer Drug Des., 6, 531-538 (1991).
S. T. Crooke, "Therapeutic Applications of Oligonucleotides," Ann. Rev. Pharmacol. Toxicol., 32, 329-376 (1992).
Chubb et al., "Human Therapeutics Based on Triple Helix Technology," TIBTECH, 10(4), 132-136 (1992).
Agrawal et al., "Antisense Oligonucleotides: Gene Regulation and Chemotherapy of AIDS," A

Affiliated with

Also associated with

Rating

2'-O-alkylated oligoribonucleotides and phosphorothioate analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 2'-O-alkylated oligoribonucleotides and phosphorothioate analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2'-O-alkylated oligoribonucleotides and phosphorothioate analogs will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-364435